TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 203832
Drug: Pure nicotinic
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure nicotinic acid (3 to 4 g/daily) or its esters (4 to 6 g/daily) or beta-Pyridylcarbinol (800 to 1200 mg/daily)
Study: 203832
Drug: Increased dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosage of nicotinic acid
Study: 26216919
Drug: Choice-based reality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice-based reality therapy
Study: 25880805
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg od
Study: 23674107
Drug: Nebulized isotonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized isotonic saline (3 mL)
Study: 23674107
Drug: Nebulized water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized water (3 mL)
Study: 19695391
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg orally dispersible tablet
Study: 19695391
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg orally dispersible tablet
Study: 19695391
Drug: Reference 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference 100 mg capsule
Study: 17041858
Drug: 16-week structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-week structured treatment interruption (STI) followed by optimized ART
Study: 10654902
Drug: Low-dose estrogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen patch (0.05 mg applied twice weekly for 4 weeks)
Study: 10654902
Drug: High-dose estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose estrogen patch (0.10 mg applied twice weekly for 4 weeks)
Study: 8375373
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g lecithin.kg body mass-1 before exercise
Study: 8375373
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g lecithin.kg body mass-1 without exercise
Study: 3093237
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg lithium carbonate daily for 3 weeks
Study: 3093237
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (3 nights during therapy)
Study: 3093237
Drug: Post-treatment (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (2 registrations after lithium carbonate was discontinued)
Study: 24814890
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (three doses)
Study: 18801404
Drug: Buprenorphine (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (highest dose 32 mg/day)
Study: 18801404
Drug: Methadone (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (highest dose 200 mg/day)
Study: 15739214
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (LAS, TS, and nifedipine)
Study: 14716878
Drug: 131I-HAb18F(ab')2 injected
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 131I-HAb18F(ab')2 injected into the target hepatic artery at doses of 0.5, 0.75, 1.0 mCi/kg
Study: 10362732
Drug: L-NMMA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (4 mg. kg-1. h-1)
Study: 10362732
Drug: L-NAME (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (75 or 180 micrograms . kg-1. h-1)
Study: 27411361
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with AV delay optimization
Study: 27411361
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with reduced LV activation time
Study: 24255104
Drug: Salsalate 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate 3.5 g/day for 48 weeks
Study: 22971188
Drug: High UVA-protection
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High UVA-protection sunscreen applied at 2 mg/cm²
Study: 22971188
Drug: Low UVA-protection
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low UVA-protection sunscreen applied at 2 mg/cm²
Study: 22971188
Drug: High UVA-protection
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High UVA-protection sunscreen applied at 1 mg/cm²
Study: 22971188
Drug: Low UVA-protection
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low UVA-protection sunscreen applied at 1 mg/cm²
Study: 19200365
Drug: RCT (50.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later
Study: 19200365
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups receive adjuvant chemotherapy (12 weeks continuous infusional 5-FU)
Study: 17095923
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg(‐1) body mass in 1 L of fluid)
Study: 11354392
Drug: Clarithromycin MR
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin MR 500 mg once daily
Study: 11354392
Drug: Clarithromycin IR
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin IR 250 mg twice daily
Study: 3155334
Drug: Dentine adhesives
Normalized name: dendropanax dentiger root with stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentine adhesives and composites used in combination
Study: 31852207
Drug: Sevoflurane +
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane + high-dose remifentanil (SH)
Study: 31852207
Drug: Sevoflurane +
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane + low-dose remifentanil (SL)
Study: 31852207
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + high-dose remifentanil (PH)
Study: 31076468
Drug: ICH-1 formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICH-1 formula (12.1% treatment-emergent adverse events)
Study: 31076468
Drug: Placebo (5.8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5.8% treatment-emergent adverse events)
Study: 31076468
Drug: ICH-2 formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICH-2 formula (2.8% treatment-emergent adverse events)
Study: 28266765
Drug: OCV-C02 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCV-C02 (0.3 mg/body)
Study: 28266765
Drug: OCV-C02 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCV-C02 (1 mg/body)
Study: 28266765
Drug: OCV-C02 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCV-C02 (3 mg/body)
Study: 28266765
Drug: OCV-C02 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCV-C02 (6 mg/body)
Study: 28266765
Drug: OCV-C02 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCV-C02 (0.3 to 6 mg/body)
Study: 14678271
Drug: Nicotinamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (4 g orally, total dose of 8 g)
Study: 11936571
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28) + Dextroamphetamine (20 mg on Days 22-28)
Study: 11936571
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28)
Study: 11928147
Drug: IMZ implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMZ implant
Study: 11928147
Drug: Clinical Implant
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Implant Performance scale (CIP)
Study: 7774069
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CSA) at doses <5 mg/kg/day
Study: 5077919
Drug: Spontaneous reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous reporting of adverse reactions to drugs
Study: 27712461
Drug: Cyanoacrylate treatment
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanoacrylate treatment (n = 218 teeth)
Study: 27712461
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (n = 216 teeth)
Study: 25791540
Drug: Intramuscular olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular olanzapine (10 mg)
Study: 25791540
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (5 mg) plus lorazepam (2 mg)
Study: 23335971
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions over 2 months, 5 days/week, 90 minutes each, 100% oxygen at 2 ATA
Study: 23335971
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cross group) - no treatment for 2 months followed by 40 HBOT sessions
Study: 16940980
Drug: CPT-11 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (90 mg/m(2) three times weekly) concomitant to hyperfractionated accelerated radiotherapy (HART)
Study: 9129484
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100
Study: 9129484
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100 and 0200
Study: 7964948
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) at a dosage of 30 to 38 Gy in 2- to 3.6-Gy fractions
Study: 3581696
Drug: Cytotoxic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic drug treatment (T-group)
Study: 3581696
Drug: Symptomatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic drugs only (NT-group)
Study: 23238223
Drug: modified constraint
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint induced movement therapy (mCIMT)
Study: 16611388
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg policosanol daily for 12 weeks
Study: 27101581
Drug: IV Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Methotrexate (MTX), 0.4 mg/kg daily for 5 days every 14 days (25 mg maximum daily dose)
Study: 27101581
Drug: IV Actinomycin-D
Normalized name: ACTINOMYCIN-D
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Actinomycin-D (Act-D), 1.25 mg/m (2 mg maximum dose) every 14 days
Study: 15676045
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (1 mg Bupi and 0.1 mg HA)
Study: 15676045
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (0.5 mg Bupi and 0.1 mg HA)
Study: 15676045
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (1 mg Bupi and 0 mg HA)
Study: 12324672
Drug: BEC‐HFA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEC‐HFA 500 micro g/day
Study: 12324672
Drug: BEC‐HFA 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEC‐HFA 1000 micro g/day
Study: 12324672
Drug: FLU‐HFA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU‐HFA 500 micro g/day
Study: 12324672
Drug: FLU‐HFA 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU‐HFA 1000 micro g/day
Study: 11776508
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of GnRH antagonist (Cetrotide)
Study: 11776508
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of GnRH antagonist (Cetrotide)
Study: 9438891
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron 0.05 mg/kg
Study: 9438891
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron 0.1 mg/kg
Study: 9438891
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron 0.15 mg/kg
Study: 9438891
Drug: oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.05 mg/kg
Study: 9438891
Drug: oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.1 mg/kg
Study: 9438891
Drug: oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.15 mg/kg
Study: 8339493
Drug: Weight bearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight bearing during treatment
Study: 23672055
Drug: Zaoren Anshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaoren Anshen capsules (five capsules)
Study: 23672055
Drug: Zaoren Anshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaoren Anshen capsules
Study: 8807172
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 lidocaine
Study: 30141289
Drug: Ciloprost (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciloprost (100 mg, twice a day)
Study: 24377889
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine (2 mg)
Study: 18983695
Drug: Intensive dose
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dose of renal replacement therapy
Study: 18983695
Drug: Less-intensive dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-intensive dose of renal replacement therapy
Study: 14620915
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of IgG and IgM anti-MUC1 antibodies
Study: 14620915
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of SM3 antibody
Study: 27007018
Drug: Oral Impact
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Impact
Study: 19858141
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (antihypertensive medication)
Study: 16965225
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) monotherapy 500 mg twice daily in slow running infusion for twelve days followed by oral administration of 500 mg twice daily until delivery
Study: 16965225
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) monotherapy 3x250 mg daily
Study: 16965225
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of UDCA and SAMe
Study: 11009047
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg b.i.d.) with mirtazapine (30 mg nocte)
Study: 11009047
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with mirtazapine (30 mg nocte)
Study: 8406286
Drug: Other lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other lipid-lowering agents
Study: 8406286
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further medication
Study: 2949396
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg b.i.d. for 14 days
Study: 31712838
Drug: Palpation-guided corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided corticosteroid injection
Study: 29883964
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/kg/h)
Study: 21074212
Drug: Index tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index tumor volume threshold of 0.5 ml
Study: 17233236
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum in combination with counseling (motivational interviewing or health education)
Study: 17233236
Drug: Placebo gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gum in combination with counseling (motivational interviewing or health education)
Study: 9798802
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (1.2 mg)
Study: 9798802
Drug: Biperiden (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (5 mg)
Study: 7636454
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan (6 mg per dose, one or two doses for a single migraine episode)
Study: 7636454
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Acetaminophen
Study: 2197532
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pentamidine in 6 ml Aqua dest. with Inspiratory vital capacity breathing
Study: 2197532
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg pentamidine in 6 ml Aqua dest.
Study: 31081480
Drug: dual‐disorder treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dual‐disorder treatment of PTSD and SUD using prolonged exposure
Study: 31081480
Drug: single‐disorder relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: single‐disorder relapse prevention treatment for SUD
Study: 27880052
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided BoNT‐A injections
Study: 27880052
Drug: Electromyographic guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyographic guided BoNT‐A injections
Study: 19345145
Drug: TK-cells infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TK-cells infusion
Study: 11177331
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin once daily (1.5 mg/kg)
Study: 11177331
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin twice daily (1.0 mg/kg)
Study: 7889194
Drug: TCV-116 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 at 4 mg/day for 4 weeks
Study: 4612057
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg morphine intravenously
Study: 25106891
Drug: GnRHa therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa therapy (1.2 mg daily as nasal spray for 4 weeks before and 4 weeks after surgery)
Study: 16100298
Drug: Darifenacin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 75 mg
Study: 12047487
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release paracetamol (SR paracetamol), 4 g/day (two 665 mg tablets taken three times daily)
Study: 12047487
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release paracetamol (IR paracetamol), 4 g/day (two 500 mg tablets taken four times daily)
Study: 7032826
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg three times a day)
Study: 7032826
Drug: Captopril (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (200 mg three times a day) + Placebo
Study: 31679812
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group visits sessions (n=55)
Study: 25450709
Drug: Besifovir 90
Normalized name: Besifovir
DrugBank: Besifovir (DB15671)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifovir 90 mg
Study: 25450709
Drug: Besifovir 150
Normalized name: Besifovir
DrugBank: Besifovir (DB15671)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifovir 150 mg
Study: 16732214
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia with propofol sedation and sub-Tenon's anaesthesia (lidocaine/mercaine infusion)
Study: 10028206
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for 20 weeks
Study: 2054266
Drug: Plain paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain paracetamol tablets 1000 mg every 6th hour
Study: 2054266
Drug: Paracetamol slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol slow-release tablets 2000 mg every 12th hour
Study: 6666216
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg orally administered ISDN
Study: 31398634
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily routine exercises)
Study: 15257922
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy combined with concomitant chemotherapy